Education
About Us
Working with TipRanks
Follow Us
West Pharmaceutical Services, Inc. (WST)
NYSE:WST
RESEARCH TOOLSreports
WST Analyst Ratings
Strong Buy
7 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
WST Stock 12 Month Forecast
Average Price Target
$295.00
▲(39.80%Upside)
| Highest Price Target$370.00 | Average Price Target$295.00 | Lowest Price Target$245.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TipRanks
$228
Hold
8.05%
Upside
Downgraded
05/22/25
West Pharmaceutical Services' strong financial performance and positive earnings guidance are notable strengths, supporting the company's long-term growth and stability. However, technical analysis and valuation metrics indicate cautious market sentiment and high expectations. The earnings call provides a balanced view with both opportunities and challenges, resulting in a moderate overall score.
Citi
$300
Buy
42.17%
Upside
Reiterated
05/22/25
Bank of America Securities
―
Buy
―
Reiterated
05/16/25
Jefferies
$240→$245
Buy
16.10%
Upside
Reiterated
04/25/25
Evercore ISI
$275
Buy
30.32%
Upside
Reiterated
04/25/25
William Blair
―
Buy
―
Reiterated
04/24/25
UBS
$285
Buy
35.06%
Upside
Reiterated
03/19/25
DBS
$370
Buy
75.34%
Upside
Reiterated
03/03/25
Strong Market Position and Growth Potential Drive Buy Rating for West Pharmaceutical ServicesWe rate West with a BUY and TP of US$275 We rate West with a BUY and TP of West is a market leader in pharmaceutical packaging with elastomers. West is a market leader in pharmaceutical packaging with elastomers. West is the largest elastomer supplier for drug makers globally, with products including vial stoppers and syringe plungers. The demand for packaging is growing, with global daily medicine dosage increasing from c.3 trillion doses in 2018 to c.3.4 trillion doses in 2023. The increased dosages would translate into higher demand for packaging materials such as elastomers. West will be able to leverage on the uptrend. Much lower price pressure, higher revenue certainty. Much lower price pressure, higher revenue certainty.
KeyBanc
$325
Buy
54.01%
Upside
Reiterated
02/14/25
Deutsche Bank
$250
Buy
18.47%
Upside
Upgraded
02/14/25
Wolfe Research
―
Hold
―
Initiated
12/13/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TipRanks
$228
Hold
8.05%
Upside
Downgraded
05/22/25
West Pharmaceutical Services' strong financial performance and positive earnings guidance are notable strengths, supporting the company's long-term growth and stability. However, technical analysis and valuation metrics indicate cautious market sentiment and high expectations. The earnings call provides a balanced view with both opportunities and challenges, resulting in a moderate overall score.
Citi
$300
Buy
42.17%
Upside
Reiterated
05/22/25
Bank of America Securities
―
Buy
―
Reiterated
05/16/25
Jefferies
$240→$245
Buy
16.10%
Upside
Reiterated
04/25/25
Evercore ISI
$275
Buy
30.32%
Upside
Reiterated
04/25/25
William Blair
―
Buy
―
Reiterated
04/24/25
UBS
$285
Buy
35.06%
Upside
Reiterated
03/19/25
DBS
$370
Buy
75.34%
Upside
Reiterated
03/03/25
Strong Market Position and Growth Potential Drive Buy Rating for West Pharmaceutical ServicesWe rate West with a BUY and TP of US$275 We rate West with a BUY and TP of West is a market leader in pharmaceutical packaging with elastomers. West is a market leader in pharmaceutical packaging with elastomers. West is the largest elastomer supplier for drug makers globally, with products including vial stoppers and syringe plungers. The demand for packaging is growing, with global daily medicine dosage increasing from c.3 trillion doses in 2018 to c.3.4 trillion doses in 2023. The increased dosages would translate into higher demand for packaging materials such as elastomers. West will be able to leverage on the uptrend. Much lower price pressure, higher revenue certainty. Much lower price pressure, higher revenue certainty.
KeyBanc
$325
Buy
54.01%
Upside
Reiterated
02/14/25
Deutsche Bank
$250
Buy
18.47%
Upside
Upgraded
02/14/25
Wolfe Research
―
Hold
―
Initiated
12/13/24
Best Analysts Covering West Pharmaceutical Services
1 Month
xxx
Success Rate
6/11 ratings generated profit
Average Return
+0.60%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 54.55% of your transactions generating a profit, with an average return of +0.60% per trade.
3 Months
xxx
Success Rate
7/11 ratings generated profit
Average Return
+6.46%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 63.64% of your transactions generating a profit, with an average return of +6.46% per trade.
1 Year
Success Rate
7/11 ratings generated profit
Average Return
+11.86%
reiterated a buy rating 3 months ago
Copying Paul Knight's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +11.86% per trade.
2 Years
xxx
Success Rate
6/11 ratings generated profit
Average Return
+17.03%
reiterated a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 54.55% of your transactions generating a profit, with an average return of +17.03% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
WST Analyst Recommendation Trends
Rating
Jan 25
Feb 25
Mar 25
Apr 25
May 25
Strong Buy
0
1
2
2
1
Buy
4
6
7
10
9
Hold
1
1
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
5
8
9
12
10
Each month's total comprises the sum of three months' worth of ratings.
WST Financial Forecast
WST Stock Forecast FAQ
What is WST’s average 12-month price target, according to analysts?
Based on analyst ratings, West Pharmaceutical Services, Inc.’s 12-month average price target is 295.00.
What is WST’s upside potential, based on the analysts’ average price target?
West Pharmaceutical Services, Inc. has 39.80% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is WST a Buy, Sell or Hold?
West Pharmaceutical Services, Inc. has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.
What is West Pharmaceutical Services, Inc.’s price target?
The average price target for West Pharmaceutical Services, Inc. is 295.00. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $370.00 ,the lowest forecast is $245.00. The average price target represents 39.80% Increase from the current price of $211.02.
The highest analyst price target is $370.00 ,the lowest forecast is $245.00. The average price target represents 39.80% Increase from the current price of $211.02.
What do analysts say about West Pharmaceutical Services, Inc.?
West Pharmaceutical Services, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.
How can I buy shares of WST?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.